Glioblastoma IDH wild-type (with pseudoprogression)

Case contributed by A.Prof Frank Gaillard



Patient Data

Age: 70 years
Gender: Male

There is am intraaxial peripherally enhancing mass in the peripheral right middle frontal gyrus. There is surrounding abnormal hyperintensity in the surrounding right frontal white matter consistent with vasogenic oedema. Blooming on gradient echo sequence indicate the presence of blood products within the mass. Diffusion weighted imaging sequences difficult to interpret any presence of blood products.

A second smaller focus of enhancement is present anterior and medial to the larger lesion.

Previous right posterior cerebral artery territory infarct.

Conclusion: Two closely related enhancing intra-axial masses in the right frontal lobe either represent haemorrhagic metastases or a haemorrhagic high grade glial tumour (GBM). 

The patient went on to have a resection. 


MICROSCOPIC DESCRIPTION: Sections show a hypercellular tumour composed of sheets of tumour cells with extensive areas of pallisaded tumour necrosis. There is focal microvascular proliferation with multilayering of atypical cells around vessel lumena. Tumour cells contain abundant eosinophilic cytoplasm, oval angulated nuclei with coarse granular chromatin and small nucleoli. Frequent mitoses are observed.


  • GFAP Positive
  • Nestin Positive (high)
  • IDH-1 R132H Negative (not mutated)
  • ATRX Positive (not mutated)
  • MGMT Negative (likely methylated)
  • p53 Positive
  • p16 CDKN2A Positive
  • Topoisomerase labelling index: Approximately 20%.

The features are of glioblastoma, IDH wildtype (WHO grade IV). 


Immediate post-op scan (not shown) demonstrated complete resection of the enhancing component. The patient went on to receive routine Stupp protocol (radiotherapy and temozolomide). 

Follow up scanning (not shown) showed a small amount of developing enhancement at ~10 weeks post surgery. 


MRI brain 7 months post surgery

Right frontal craniotomy. Underlying this is a right enhancing frontal mass with marked increase of surrounding FLAIR hyperintensity, which crosses the midline at the genu of the corpus callosum and extends to the posterior frontal lobe. Effacement of the frontal horn of the right lateral ventricle with subfalcine herniation and leftward midline shift of 4.5 mm. No hydrocephalus.

Mild diffusion restriction surrounds the resection cavity. On MR spectroscopy in the enhancing component of the mass there is increased lactate with depressed choline, creatine, and NAA. Minimal cerebral blood volume on perfusion imaging some of which may be the result of susceptibility effect from blood product.

Conclusion: Marked increase in the enhancing mass and FLAIR signal. Advanced imaging gives somewhat conflicting results, with the low ADC and the mass effect suggesting progressive high-grade disease, but the lack of significant choline elevation and large lactate peak on spectroscopy favouring radiation necrosis. This is further supported by low CBV although interpretation of this is complicated by blood product.

Overall appearances in the context of a MGMT methylated tumour, 7 months post surgery, favour pseudoprogression being the dominant process. 

The patient proceeded to re-resection. 


MICROSCOPIC DESCRIPTION: The sections show small areas with features of high grade astrocytoma. These show dense hypercellularity, marked nuclear and cytoplasmic pleopmorphism, multilayering of atypical cells around microvessel lumena and areas of necrosis. No immunostaining for MGMT is seen in tumour cell nuclei. Topoisomerase labelling index: Approximately 10%

The majority of the specimen, however, shows florid reactive gliosis and neovascularisation (not hyperplastic microvascular proliferation as seen in tumour) and areas of infarct-like necrosis (bottom left corner). Nuclear MGMT staining is preserved in these areas (note the tumour was methylated, thus this is suggestive or normal cells) and the features are most consistent with post irradiation/post-chemotherapy effect.

DIAGNOSIS: Recurrent glioblastoma IDH-1 wild type with florid reactive changes most consistent with post-irradiation/post-chemotherapy effect.

Case Discussion

This case illustrates the importance of remembering that favouring pseudoprogression does not mean that no tumour will be present if biopsied, but rather that the apparent growth (i.e. progression) is due to treatment effect rather than true tumour growth. 

The importance of this is that it will determine whether management should change (e.g. shift into second line salvage therapy) or push on. Prognostically pseudoprogression is probably desirable reflecting pronounced treatment effect. This is further supported by the fact that it is seen more frequently in tumours that are MGMT methylated. 

PlayAdd to Share

Case information

rID: 46093
Published: 24th Jun 2016
Last edited: 21st May 2017
Inclusion in quiz mode: Included

Updating… Please wait.

Alert accept

Error Unable to process the form. Check for errors and try again.

Alert accept Thank you for updating your details.